BioSpace News Archive

Biotech Bay

Doctors Announce Nationwide Stand on September 17 to End America’s Firearms Epidemic

Healthcare Providers Across the U.S. Act to End “Public Health Crisis”

September 12, 2018
·
3 min read
Drug Development

JANSSEN’S TREMFYA®▼ IMPROVES LONG-TERM PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Janssen Pharmaceutical Companies of Johnson & Johnson has announced new data that show considerable improvements in long-term patient-reported outcomes (PRO) in patients switched to TREMFYA® (guselkumab) after an initial inadequate response to adalimumab.

September 12, 2018
·
14 min read
Policy

FDA acknowledges youth e-cigarette use has hit epidemic proportions

Statement by Robin Koval, CEO & President, Truth Initiative® on FDA Commissioner Scott Gottlieb’s announcement that e-cigarette use among youth has hit epidemic proportions

September 12, 2018
·
2 min read
BioForest

American Society of Hematology to Launch Sickle Cell Disease Clinical Trials Network

The American Society of Hematology (ASH) is launching a sickle cell disease (SCD) clinical trials network in order to accelerate the development of new therapies for a patient community that has very few treatments and curative options.

September 12, 2018
·
4 min read
BioMidwest

Timing May Be Everything When Taking Meds

Database Links Body’s Genetic Rhythms to Drug Metabolism in Human Tissues

September 12, 2018
·
4 min read
Duchesnay Inc. to Present a Poster on the Efficacy and Safety of Ospemifene in Menopausal Women with Moderate to Severe Vaginal Dryness at 2018 Annual Meeting of the North American Menopause Society (NAMS)

Duchesnay Inc. announced today that it will present a poster on the topic of ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS) in San Diego.

September 12, 2018
·
2 min read
Targovax Announces Publication of New Oncolytic Virus Data in the Journal of Medical Virology and Cancer Gene Therapy

Validation of ONCOS-102 potential to generate tumor-specific immune responses in vivo

September 12, 2018
·
2 min read
Drug Development

Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial

Efficacy endpoints including ≥75% and 90% reduction in the Psoriasis Area and Severity Index (PASI 75, PASI 90) were achieved following 12 weeks of treatment with ≥3 mg daily of BMS-986165

September 12, 2018
·
6 min read
Business

sk:n Clinics and Kleresca® Announce National Partnership Making the Kleresca® Biophotonic Technology Available Across the UK

k:n and Kleresca® have announced a comprehensive partnership making the innovative biophotonic technology of Kleresca® available nationwide in the UK.

September 12, 2018
·
2 min read
FDA

Celltrion Announces FDA Oncologic Drugs Advisory Committee Meeting Schedule for Proposed Biosimilar to Rituxan® (Rituximab)

Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has scheduled the Biologics License Application (BLA) for CT-P10

September 12, 2018
·
2 min read